-transparent.png){kind=logo}
In 34 patients with severe rheumatoid arthritis the therapeutic efficacy of 600 mg/die of D-penicillamine was evaluated for five years. Patients were included in the study only if the duration of their disease exceeded 6 months (upper limit 12 months), and there was involvement of 6 or more joints and an elevated erythrocyte sedimentation rate (1 Hour values greater than or equal to 25 mm). In 9 patients (26%) a decline in the activity index could be observed, but 7 of these subjects had a deterioration of findings as assessed by x-ray. The increase of the activity index indicated no therapeutic benefit in 25 patients (74%), which could be confirmed in all subjects by x-ray.
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
February 1976,
Die Medizinische Welt,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
August 1969,
Die Medizinische Welt,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
January 1973,
Zeitschrift fur Rheumaforschung,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
April 1970,
Medizinische Klinik,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
January 1981,
Zeitschrift fur Rheumatologie,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
August 1961,
Zeitschrift fur Rheumaforschung,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
April 1968,
Die Medizinische Welt,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
October 1970,
Medizinische Klinik,
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
August 1986,
Ryumachi. [Rheumatism],
H Rautenstrauch, and
W Laschner, and
J G Saal, and
P Fritz
January 1976,
Verhandlungen der Deutschen Gesellschaft fur Rheumatologie,
